Pulling every public source in parallel and triangulating across them. A fresh assembly takes about 40 seconds — it’s cached after, so you’ll come back to it instantly.
exact filed revenue; product-level is a separate labelled extraction · 187ms
AI synthesis onAsk-us email onAlerts agent on
100
Trials tracked
23
Active Phase 3
2
FDA approvals
119
Indications studied
12
Companies citing it
20
Quarterly filings
Analyst synthesis
AI-composed from corroborated facts · claude-sonnet-5
Semaglutide: Novo Nordisk's GLP-1 franchise anchor, deeply entrenched but drawing intensifying competitive and payer scrutiny
Positioning
Semaglutide (Ozempic, Rybelsus, Wegovy) is Novo Nordisk's flagship GLP-1 receptor agonist, spanning type 2 diabetes glycemic control and cardiovascular risk reduction, and sits within a 13+ product Novo portfolio that reinforces the company's leadership in the GLP-1 analogue class.
Lifecycle management
Patent protection extends to ~Feb 17, 2041 with exclusivity through Mar 19, 2029, and 40 patents underpin a long protected runway; active lifecycle work includes 10 follow-on/formulation/indication-expansion studies across 119 conditions and an oral-administration convenience angle (11 studies), pointing to sustained franchise broadening beyond the current label.
Clinical benefit
Approved indications cover adjunctive glycemic control in adults with type 2 diabetes and reduction of major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke) in high-risk type 2 diabetes patients, with 119 studied indications and 32 Phase 3 trials signaling continued evidence generation beyond the core label.
Market & launch
The asset is in a launch/peri-launch phase with 2 rollout signals and heavy commercial visibility — 20 SEC filings and 19 news items across 12 companies — reflecting both Novo's own commercialization and the broader ecosystem of firms referencing semaglutide (e.g., device, delivery, and combination-therapy players).
Pricing & access
French HTA (HAS) data show restricted reimbursement for Wegovy tied to specific BMI criteria, indicating conditional rather than broad access for the obesity indication, while Ozempic and generic-semaglutide HAS records remain unclear/undecided; no cross-country comparison is possible from the available records.
Threats & watch-outs
The competitive field is contested, with 63 sponsors running trials touching this molecule or its class, and post-market safety attention (nausea, off-label use, vomiting) could shape prescribing caution or label evolution; despite a long patent runway to 2041, 2 recent patent/exclusivity/generic-related headlines suggest early positioning by follow-on entrants, and restricted payer access in at least one major market signals potential friction in obesity-indication reimbursement expansion.
CI picture
Classic CI views — set a role to weight the SWOT to your perspective
Strengths
▪Long exclusivity runway (patent to 2041, exclusivity to 2029, 40 patents) securing branded revenue window
▪Dual approved indications (glycemic control and CV risk reduction) with broad evidentiary base (119 studied indications, 32 Phase 3 trials)
▪Multi-brand, multi-formulation footprint (Ozempic, Rybelsus, Wegovy) within a deep Novo portfolio
▪Positive-leaning sentiment (net +0.20, social +0.40) suggesting strong patient/prescriber engagement
Weaknesses
▪Restricted HTA reimbursement in France for Wegovy tied to narrow BMI criteria, limiting broad obesity-market access
▪Unclear reimbursement status for Ozempic and generic semaglutide in the same market, creating access ambiguity
▪Post-market safety signals (nausea, vomiting, off-label use) that could invite scrutiny or utilization management
Opportunities
▪Active lifecycle management (10 follow-on studies across 119 conditions) supports indication and formulation expansion
Biggest competitors
Who can take share right now — external rivals named upfront, with the company. The originator's own successor drugs are shown separately as portfolio strategy, not counted as threats.
The classic CI phase chart: mechanism class down the side, development phase across the top. In-class and cross-MOA rivals on their own lanes, each with its manufacturer.
The rival set changes with the indication. Start on Overview, then tab into each indication.
100
Trials
79
Active
32
Phase 3
63
Rival sponsors
Competitors
Nantes University HospitalUniversity of ArizonaNovo Nordisk A/SNemours Children's ClinicBrigham and Women'sVanderbilt University MedicalRezera (formerly NodTheraUniversity Health Network,Universitaire Ziekenhuizen KUEli Lilly andThe Methodist HospitalZagazig UniversitySunnybrook Health SciencesPopulation Health ResearchAxel BrandesThe United Bio-TechnologyUniversity Medical CenterHamilton Health Sciences+45
Pipeline swim-lanes
Phase 4
13 · 10 active
Hamilton Health Sciences CorporationUniversity of Missouri-ColumbiaFundación para la Investigación del Hospital Clínico de Valencia+9
Phase 3
30 · 21 active
Universitaire Ziekenhuizen KU LeuvenEli Lilly and CompanyZagazig University+9
Phase 2
26 · 22 active
Vanderbilt University Medical CenterRezera (formerly NodThera Limited)Novo Nordisk A/S+19
Phase 1
9 · 8 active
Novo Nordisk A/SYale UniversityBoehringer Ingelheim+1
Early Ph 1
3 · 3 active
University of ArizonaSunnybrook Health Sciences CentreThe University of Hong Kong
Unspecified
19 · 15 active
Nantes University HospitalNovo Nordisk A/SNemours Children's Clinic+12
Competitive bullseye
Late-stage (Ph3) (14)Emerging / other (49)
Competitive threat · who can take share
Beyond drug class — the rivals that can eat this drug's lunch, including different-mechanism competitors treating the same patients and the oral-vs-injectable format dynamic.
Subject route: oral
Semaglutide's biggest external threat is Eli Lilly's tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 agonist showing superior weight and glycemic efficacy, though still injectable. The nearer-term format threat is oral small-molecule GLP-1 agonists like Lilly's orforglipron (pipeline, no peptide/food restrictions) which could rival oral Rybelsus's convenience while matching injectable-level efficacy. Novo's own oral semaglutide vs injectable Wegovy/Ozempic is a deliberate lifecycle/self-cannibalization strategy, not a competitive threat.
Stress-test the strategy: concrete what-if scenarios grounded in this competitive situation, each with a likelihood, horizon, business impact, and a no-regret response. Simulations, not forecasts.
Running the war-game — stress-testing the competitive situation…
Class competitors
The molecule-level competition — other approved drugs in the same ATC class, with their brand and originator. Same mechanism, different asset.
Approved indications are proven by the FDA label. In-development indications carry a modelled estimate — 90-day lag on the pivotal primary-completion date (Phase 3, or Phase 2 in oncology) — clearly an estimate, not a known date.
IndicationStatusFurthest phaseLaunch
Type 2 Diabetes
25 trials · 14 active · Novo Nordisk A/S
ApprovedPhase 4
On label ✓
Diabetes
2 trials · 1 active · University of Missouri-Columbia
ApprovedPhase 4
On label ✓
Cardiovascular Disease
2 trials · 2 active · University of Ulster
ApprovedPhase 3
On label ✓
Type 2 Diabetes (T2D)
1 trial · 1 active · Novo Nordisk A/S
Early signals
Weak, pre-consensus signals that could reshape the landscape — deliberately below the triangulation bar. Graded for confidence, surfaced for speed.
By the time something is confirmed by multiple reliable sources, the market has usually already reacted — so acting on it is late. These are the earlier, less-certain movements worth watching now. Each carries its confidence grade honestly: the value here is reaction time, not proof.
This is the general read. Set your Key Intelligence Topicsand these signals re-rank and tighten around the questions you're actually asking.
Separated by FDA application type · small molecule → generics
Innovator / originator
2
NOVO
OZEMPICNDANOVO · 2019
RYBELSUSNDANOVO · 2019
Generics
0
No FDA-approved generics yet — originator exclusivity / patents still in force.
Biosimilar / generic market entry
Approval is not launch — follow-on entry is routinely delayed years by patent settlements. This is the launch-vs-approval read.
Regulatory approval in Canada for generic semaglutide (Sandoz, Aspen Pharmacare) is not the same event as commercial launch, and none of the headlines provided specify an actual market-entry date. The Aspen headline references a Novo patent expiry as the trigger for approval, but no corresponding launch date is confirmed. In the US, the Orange Book ceiling points to Feb 17, 2041 as the conservative loss-of-exclusivity marker, though actual entry timing there—and in Canada—remains governed by patent settlements and litigation outcomes not disclosed in these facts. Until a launch date is explicitly reported, treat approval as a necessary but insufficient signal for competitive timing.
Grounded in the sourced approval dates and fetched news headlines. Launch dates set by confidential settlements are stated only where publicly reported; otherwise flagged as not publicly confirmed — never invented.
Exclusivity & loss-of-exclusivity
U.S. patents & regulatory exclusivity · FDA Orange Book (ingested), refreshed periodically
semaglutide (marketed as Ozempic, Rybelsus, Wegovy) is an identifiable, actively-referenced small-molecule asset.
High confidence
identityRxNorm RxCUI 1991302Drugs@FDA product record20 SEC filings reference the asset
Approved / marketed in the U.S. — indicated for: RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
High confidence
regulatory2 FDA product approvals1 regulatory headlinesDiscussed in SEC filings
The pivotal-trial efficacy narrative from the FDA-approved label (Section 14, Clinical Studies) — the drug's own registered evidence. Auto-compared with its nearest same-class rival; switch peers or type any drug.
Compare §14 with a competitor
Same class (ATC):
Ozempic · label §14
14.1 Overview of Clinical Studies The effectiveness of OZEMPIC tablets (1.5 mg, 4 mg and 9 mg strengths) [see Dosage and Administration ( 2.2 )] and RYBELSUS (3 mg, 7, mg and 14 mg strengths) [see Dosage and Administration ( 2.3 )] has been established as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus based on adequate and well-controlled studies of RYBELSUS in adult patients with type 2 diabetes mellitus [see Clinical Pharmacology ( 12.3 )] . Below is a display of the efficacy results of the adequate and well-controlled studies of RYBELSUS, referred to below as semaglutide tablets, in adult patients with type 2 diabetes mellitus. Semaglutide tablets have been studied as monotherapy and in combination with metformin, sulfonylureas, sodium-glucose co-transporter-2 (SGLT-2) inhibitors, insulins, and thiazolidinediones in patients with ty…
Research frontier · preprints & congresses
The leading edge — the newest preprints, congress abstracts, and journal articles, ahead of mainstream indexing. Early signals to watch, with caveats.
Payer / reimbursement assessments across 1 countries · NICE, ICER, SMC, HAS, CADTH, PBAC, G-BA
In France, semaglutide (Wegovy) received a favorable reimbursement opinion restricted to adults meeting specific BMI criteria, indicating conditional/subgroup access rather than broad reimbursement. The other French records (semaglutide generic entry and Ozempic) do not state a decision, so their status is unclear. No cross-country comparison is possible from these records alone, but the pattern within France shows restricted access tied to obesity indication criteria.
Verdicts normalised from published HTA recommendations (multilingual). Follow each link for the authoritative decision.
Vendor & supply landscape
Every company making, developing, or shipping the asset · Drugs@FDA, Orange Book, ClinicalTrials.gov, SEC, FDA shortages
On the FDA drug-shortage list
Novo Nordisk, Inc. — To Be Discontinued (Tablet) · Novo Nordisk, Inc. — To Be Discontinued (Tablet) · Novo Nordisk, Inc. — To Be Discontinued (Tablet). A listed shortage can make the drug eligible for 503A/503B compounding — expect additional compounded supply beyond the FDA-approved manufacturers below.
Originator1
NOVO NORDISK INC ·4
In development50
Ali AminianAll India Institute of Medical Sc…Antag TherapeuticsAstraZenecaAxel BrandesBeijing QL Biopharmaceutical Co.,…Boehringer Ingelheim
SEC-referenced companies
Public companies that name this asset in SEC filings
NOVO NORDISK A SNVOVivani Medical, Inc.VANIWellgistics Health, Inc.WGRXTiziana Life Sciences LtdTLSANemaura Medical Inc.NMRDGalmed Pharmaceuticals Ltd.GLMDBiomea Fusion, Inc.BMEARedHill Biopharma Ltd.RDHLConexeu Sciences Inc.CNXURight On Brands, Inc.RTONBetter Choice Co Inc.BTTRElevai Labs Inc.ELAB
▪Oral-route convenience studies (11) could differentiate Rybelsus and expand patient eligibility
▪Long protected period allows further HTA negotiations and expanded payer coverage across geographies
Threats
▪Highly contested competitive landscape with 63 sponsors developing trials in the same molecule/class
▪Early patent/exclusivity-related headlines (2) hinting at generic or biosimilar positioning well ahead of LOE
▪Restricted or unclear payer decisions may constrain revenue growth in key obesity and diabetes markets
▪Safety and off-label use patterns could trigger additional regulatory or payer review
Trends & regulatory outlook · projection
Given the long patent runway to 2041 and active Phase 3 and lifecycle programs, semaglutide is likely to see continued indication broadening and formulation innovation over the next several years, reinforcing Novo Nordisk's GLP-1 leadership. However, the intensity of competitive trial activity (63 sponsors) and mixed/restricted payer signals in at least one major market suggest that pricing and reimbursement negotiations—particularly for obesity indications—will likely become more contentious, and early patent-related headlines warrant monitoring for potential erosion pressure well before formal exclusivity expiry.
Milestone timeline
ApprovalTrial readoutExclusivityPatentLoss of exclusivity
Pipeline swim-lanes
Phase 4
13 · 10 active
Hamilton Health Sciences CorporationUniversity of Missouri-ColumbiaFundación para la Investigación del Hospital Clínico de Valencia+9
Phase 3
30 · 21 active
Universitaire Ziekenhuizen KU LeuvenEli Lilly and CompanyZagazig University+9
Phase 2
26 · 22 active
Vanderbilt University Medical CenterRezera (formerly NodThera Limited)Novo Nordisk A/S+19
Phase 1
9 · 8 active
Novo Nordisk A/SYale UniversityBoehringer Ingelheim+1
Early Ph 1
3 · 3 active
University of ArizonaSunnybrook Health Sciences CentreThe University of Hong Kong
Unspecified
19 · 15 active
Nantes University HospitalNovo Nordisk A/SNemours Children's Clinic+12
Competitive bullseye · threat proximity
Direct marketed threats (6)Threatening pipeline (2)Emerging / other (27)Academic / non-commercial (36)
The inner ring is direct marketed threats — same-class rivals plusjudged cross-mechanism competitors selling now. The next ring is threatening pipeline agents; outer rings are this molecule's own follow-ons.
Academic, hospital and cooperative-group sponsors are shown on the outer ring, not ranked as commercial threats — they are typically the research site for an investigator-initiated study.
SWOT & outlook are AI analysis grounded in the sourced facts below — a reasoned read, not established fact.
retatrutide
Eli Lilly
Cross-mechanism · pipeline
Triple agonist showing best-in-class weight loss in trials; could leapfrog both semaglutide and tirzepatide in obesity/diabetes.
These are the rivals most able to take share from semaglutideright now — company named, each one a click into its own dossier. The full ranked assessment (incl. pipeline & cross-mechanism) is further down.
Same maker · portfolio / lifecycle strategy — NOT external threats
Novo Nordisk's own successor assets — Victoza — are taking share from semaglutideby design. That is a franchise-defence / lifecycle play, not a competitive loss. Treating a company's own drugs as its rivals is a credibility error, so they're called out here separately.
SubjectExternal competitorSame-maker successor (portfolio)
Mechanism class × development phase. Same-maker successors are the originator's own lifecycle strategy, marked distinctly — not counted as external threats. Phase & class are an analyst read; drugs are verified to exist.
(FOUNDAYO)
High threat
Marketed
Same class
· oral
Oral once-daily small molecule with no food/water restrictions (unlike Rybelsus), potentially matching injectable efficacy; major convenience threat.
Format/route — Oral vs oral: removes Rybelsus's absorption/dosing restrictions, a direct convenience upgrade over Novo's oral GLP-1.
Another oral small-molecule GLP-1 candidate; development has faced tolerability/formulation setbacks but remains a watch item for oral market disruption.
Format/route — Oral vs oral competitor to Rybelsus; could offer simpler dosing if development succeeds.
An AI competitive judgement — who can take share, across mechanisms and routes — with every named drug verified against FDA (marketed) or ClinicalTrials.gov (pipeline). Reasoning, not established fact; unverifiable names are dropped, never shown.
2005-04-28
Same ATC pharmacological class · brand & originator from Drugs@FDA. Click any drug to open its own dossier.
Approved
Pre-clinical
On label ✓
Cardiovascular Disease (CVD)
1 trial · 1 active · Novo Nordisk A/S
ApprovedPre-clinical
On label ✓
Cardiovascular Risk
1 trial · 1 active · All India Institute
ApprovedPhase 3
On label ✓
Cardiovascular Events
1 trial · 1 active · Brigham and Women's
ApprovedPre-clinical
On label ✓
Diabetes Mellitus, Type 1
1 trial · 1 active · Novo Nordisk A/S
ApprovedPhase 1
On label ✓
Obesity & Overweight
9 trials · 8 active · Nantes University Hospital
In developmentPhase 4
~2023-10-09
est. · Phase 3 PCD 2023-07-11
Alzheimers Disease
1 trial · Novo Nordisk A/S
In developmentPhase 3
~2024-11-17
est. · Phase 3 PCD 2024-08-19
Obese Diabetics
1 trial · Zagazig University
In developmentPhase 3
~2026-06-15
est. · Phase 3 PCD 2026-03-17
Obese Non Diabetic
1 trial · Zagazig University
In developmentPhase 3
~2026-06-15
est. · Phase 3 PCD 2026-03-17
Estimate basis: pivotal primary-completion date (PCD) + lag. Non-oncology uses the Phase 3 PCD; oncology uses the Phase 2 PCD where accelerated approval applies. Actual market launch typically trails the estimate by ~9–15 months of review — this marks the earliest plausible window, for calibration against real trends, not a promised date.
Medium
2 news items touching litigation or generic/biosimilar entry — e.g. “Sandoz Gets Canada Approval for Generic Version of Ozempic”.
Why it matters — An IP dispute can move generic or biosimilar entry — and the revenue cliff — by years in either direction.
Emerging· News
Possible label expansion into Obesity
Medium
27 trials studying Obesity, up to Phase 4 — an indication outside the current approved label.
Why it matters — A new indication would enlarge the addressable market and bring in a different competitive set than today's.
Near-term· Trials
Possible label expansion into Diabetes Mellitus
Medium
15 trials studying Diabetes Mellitus, up to Phase 4 — an indication outside the current approved label.
Why it matters — A new indication would enlarge the addressable market and bring in a different competitive set than today's.
Near-term· Trials
Possible label expansion into Diabetes
Medium
14 trials studying Diabetes, up to Phase 4 — an indication outside the current approved label.
Why it matters — A new indication would enlarge the addressable market and bring in a different competitive set than today's.
Near-term· Trials
Novo Nordisk A/S advancing a Phase 4 program
Medium
Novo Nordisk A/S has a Phase 4 program in this space but no approval yet — a challenger building a position before it shows up in the approval record.
Why it matters — An emerging entrant can reshape share and pricing well before launch; watching it now buys reaction time.
Near-term· Trials
Hamilton Health Sciences Corporation advancing a Phase 4 program
Medium
Hamilton Health Sciences Corporation has a Phase 4 program in this space but no approval yet — a challenger building a position before it shows up in the approval record.
Why it matters — An emerging entrant can reshape share and pricing well before launch; watching it now buys reaction time.
Near-term· Trials
Use code
11318191
Feb 17, 2041
U-4418
11478533
May 13, 2040
U-3861
11833248
Feb 1, 2039
U-4387
12396953
Feb 1, 2039
U-4387
12295988
Oct 10, 2038
U-2628
12551536
Oct 10, 2038
U-4418
12029779
Oct 10, 2038
U-4418
12214017
Aug 24, 2038
U-4418
11752198
Aug 24, 2038
U-4418
10888605
Aug 24, 2038
U-4418
Patents are those the sponsor listed in the FDA Orange Book. A use code(U-###) ties a patent to one specific approved use, so a generic can sometimes launch for other uses before it expires (a “skinny label”); patents without a use code are typically drug-substance or drug-product patents covering the molecule or formulation. Listed expiry is the latest date the patent could block a generic — it does not account for pediatric exclusivity (+6 months), later-filed patents, or the outcome of patent litigation and settlements, which frequently move the effective date. The loss-of-exclusivity horizon above is the latest listed patent or exclusivity date, a conservative ceiling rather than a guaranteed date.
Newest-first from Europe PMC. Preprints are not peer-reviewed and congress abstracts are early, often unpublished data — leading indicators to watch, not settled evidence.
Brigham and Women's Hospital
Cascade Pharmaceuticals, Inc
Children's Hospital Los Angeles
City of Hope Medical Center
Eli Lilly and Company
Emma Svennberg
Foundation for Atlanta Veterans E…
Fundación para la Investigación d…
Hamilton Health Sciences Corporat…
Hospices Civils de Lyon
Insel Gruppe AG, University Hospi…
Kailera
Karolinska Institutet
+30
Referenced (SEC)11
Better Choice Co Inc.Biomea Fusion, Inc.Conexeu Sciences Inc.Elevai Labs Inc.Galmed Pharmaceuticals Ltd.Nemaura Medical Inc.RedHill Biopharma Ltd.Right On Brands, Inc.Tiziana Life Sciences LtdVivani Medical, Inc.Wellgistics Health, Inc.